ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
Life Sciences
Volume 79, Issue 6, 4 July 2006, Pages 606-612
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (344 K)

 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.lfs.2006.02.025    How to Cite or Link Using DOI (Opens New Window)
Copyright © 2006 Elsevier Inc. All rights reserved.

Effects of bicyclol on dimethylnitrosamine-induced liver fibrosis in mice and its mechanism of action

Qing-Wei Hua and Geng-Tao LiuCorresponding Author Contact Information, a, E-mail The Corresponding Author, E-mail The Corresponding Author

aDepartment of Pharmacology, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing, 100050, PR China

Received 14 October 2005; 
accepted 21 February 2006. 
Available online 28 February 2006.

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Abstract

The aim was to investigate the suppressive effect of bicyclol on hepatic fibrosis induced by dimethylnitrosamine (DMN) in mice and the mechanism of its action. Hepatic fibrosis was established by intraperitoneal injection of 8 mg kg− 1 day− 1 on three consecutive days of each week for 4 or 5 weeks. In the prophylactic experiment, bicyclol (100 and 200 mg·kg− 1) was administered by gavage in association with DMN injection. For the therapeutic experiment, mice were firstly injected with DMN for 5 weeks as in the prophylactic experiment, and then the mice in drug groups were orally administered bicyclol (100 and 200 mg·kg− 1) once daily for 5 weeks. As a result, the levels of alanine aminotransferase (ALT), total bilirubin, hydroxyproline (Hyp), prolidase, tumor necrosis factor-alpha (TNFα), transforming growth factor beta-1 (TGFβ1), type I collagen in serum and the score of liver fibrosis all significantly increased in the hepatic fibrosis model group in comparison with those in control group. The treatment with bicyclol markedly reduced all the above criteria. Bicyclol also attenuated the decrease of body weight of mice, serum total protein and albumin. In addition, bicyclol treatment inhibited liver TGFβ1 and tissue inhibitor of metalloproteinase 1 (TIMP-1) mRNA expression in the prophylactic experiment. Similarly, bicyclol reduced TIMP-1 levels in liver and serum and increased collagenase activity in the liver in the therapeutic experiment. The result suggest that bicyclol attenuates DMN-induced hepatic fibrosis in mice. Its mechanisms of action may be related to the hepatoprotective and anti-inflammation properties, the down-regulation of liver TGFβ1 and TIMP-1 expression and the increase of net collagenase activity in liver.

Keywords: Bicyclol; Dimethylnitrosamine; Hepatic fibrosis; Tumor necrosis factor-alpha; Tissue inhibitor of metalloproteinase-1; Transforming growth factor beta-1; Collagenase activity

Article Outline

Introduction
Materials and methods
Materials
Animals and treatment
Histopathology
Biochemical determinations
Detection of mRNA expression
Detection of collagenase activity
Statistical analysis
Results
Discussion
Conclusion
Acknowledgements
References



Life Sciences
Volume 79, Issue 6, 4 July 2006, Pages 606-612
 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.